Morgan Stanley Issues Positive Forecast for Genmab A/S (NASDAQ:GMAB) Stock Price

Key Points

• Morgan Stanley raised Genmab’s price target from $42 to $57 while maintaining an “equal weight” rating, implying roughly 0.64% downside from the reported share price of $57.37.
• Analyst sentiment is broadly positive: TD Cowen, Guggenheim, and JPMorgan issued bullish updates, while the consensus rating is “Moderate Buy” with a target price of $53.61.
• Genmab recently exceeded quarterly expectations, reporting $0.54 in EPS versus a $0.37 estimate and $1.16 billion in revenue versus $1.12 billion expected; its shares remain near the one-year high of $59.97.

Genmab A/S (NASDAQ:GMAB - Get Free Report) had its price objective increased by Morgan Stanley from $42.00 to $57.00 in a report issued on Friday, Benzinga reports. The brokerage currently has an "equal weight" rating on the stock. Morgan Stanley's price objective points to a potential downside of 0.64% from the stock's current price.

Several other brokerages have also recently issued reports on GMAB. TD Cowen upped their target price on shares of Genmab A/S from $43.00 to $52.00 and gave the company a "buy" rating in a report on Monday. JPMorgan Chase & Co. raised Genmab A/S from a "neutral" rating to an "overweight" rating in a report on Monday. Guggenheim boosted their price objective on shares of Genmab A/S from $58.00 to $80.00 and gave the company a "buy" rating in a research note on Friday. New Street Research set a $43.00 price objective on shares of Genmab A/S in a research report on Wednesday, July 22nd. Finally, Weiss Ratings upgraded shares of Genmab A/S from a "hold (c)" rating to a "hold (c+)" rating in a research note on Tuesday, September 1st. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, Genmab A/S currently has a consensus rating of "Moderate Buy" and a consensus target price of $53.61.

Genmab A/S Price Performance

Shares of NASDAQ GMAB traded up $0.88 during midday trading on Friday, hitting $57.37. The stock had a trading volume of 4,410,995 shares, compared to its average volume of 2,457,160. The company has a quick ratio of 2.44, a current ratio of 2.46 and a debt-to-equity ratio of 0.81. The stock has a 50 day simple moving average of $36.64 and a 200-day simple moving average of $30.47. The company has a market capitalization of $35.80 billion, a PE ratio of 45.18, a P/E/G ratio of 2.47 and a beta of 0.81. Genmab A/S has a 1 year low of $23.62 and a 1 year high of $59.97.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $0.54 EPS for the quarter, beating analysts' consensus estimates of $0.37 by $0.17. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%. The business had revenue of $1.16 billion during the quarter, compared to analysts' expectations of $1.12 billion. On average, sell-side analysts expect that Genmab A/S will post 1.22 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of GMAB. Park Avenue Securities LLC lifted its stake in shares of Genmab A/S by 2.4% during the third quarter. Park Avenue Securities LLC now owns 11,258 shares of the company's stock valued at $402,000 after buying an additional 265 shares during the period. Personal CFO Solutions LLC grew its stake in Genmab A/S by 3.7% in the 1st quarter. Personal CFO Solutions LLC now owns 10,866 shares of the company's stock worth $292,000 after acquiring an additional 386 shares during the period. Versant Capital Management Inc grew its stake in Genmab A/S by 4.5% in the 3rd quarter. Versant Capital Management Inc now owns 12,235 shares of the company's stock worth $436,000 after acquiring an additional 523 shares during the period. GAMMA Investing LLC grew its stake in Genmab A/S by 16.4% in the 2nd quarter. GAMMA Investing LLC now owns 3,978 shares of the company's stock worth $109,000 after acquiring an additional 561 shares during the period. Finally, Summitry LLC raised its holdings in Genmab A/S by 5.3% in the 1st quarter. Summitry LLC now owns 11,170 shares of the company's stock valued at $300,000 after acquiring an additional 567 shares during the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Genmab A/S

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: Genmab’s cancer drug reportedly achieved the primary goals of a Phase III head-and-neck cancer study and reduced the risk of death by 50%, strengthening the potential for a meaningful new treatment option and supporting the stock’s recent move toward record highs. Genmab drug cuts death risk 50% in head and neck cancer trial
• Positive Sentiment: Guggenheim raised its Genmab price target from $58 to $80 and initiated or reiterated a “Buy” rating, implying substantial additional upside based on the trial success and broader pipeline prospects. Guggenheim Genmab recommendations
• Positive Sentiment: HC Wainwright lifted its price target from $50 to $70 while maintaining a “Buy” rating. Its updated quarterly forecasts are broadly stable to slightly higher, reinforcing expectations for earnings growth through 2027. HC Wainwright Genmab recommendations
• Positive Sentiment: Truist reaffirmed its “Buy” rating and raised its target from $45 to $67, adding to the positive sell-side momentum surrounding GMAB. Truist Genmab recommendations
• Neutral Sentiment: Some commentary suggests Genmab may still be undervalued after the trial wins, while another analysis recommends waiting before buying following the sharp rally. This highlights both continued upside potential and increased valuation and execution risk. Can Genmab Still Be Undervalued After Its Trial Wins?

Genmab A/S Company Profile

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering and developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including DuoBody and HexaBody, to create therapies designed to engage the immune system or target specific disease-related proteins.

Genmab's marketed and partnered products include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; EPKINLY (epcoritamab) for certain types of B-cell lymphoma, developed with AbbVie; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Seagen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.